Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Hybrid polar compounds, of which hexamethylenebisacetamide (HMBA) is the prototype, are potent inducers of differentiation of murine erythroleukemia (MEL) cells and a wide variety of other transformed cells. HMBA has been shown to induce differentiation of neoplastic cells in patients, but is not an adequate therapeutic agent because of dose-limiting toxicity. We report on a group of three potent second generation hybrid polar compounds, diethyl bis-(pentamethylene-N,N-dimethylcarboxamide) malonate (EMBA), suberoylanilide hydroxamic acid (SAHA), and m-carboxycinnamic acid bis-hydroxamide (CBHA) with optimal concentrations for inducing MEL cells of 0.4 mM, 2 microM, and 4 microM, respectively, compared to 5 mM for HMBA. All three agents induce accumulation of underphosphorylated pRB; increased levels of p2l protein, a prolongation of the initial G1 phase of the cell cycle; and accumulation of hemoglobin. However, based upon their effective concentrations, the cross-resistance or sensitivity of an HMBA-resistant MEL cell variant, and differences in c-myb expression during induction, these differentiation-inducing hybrid polar compounds can be grouped into two subsets, HMBA/EMBA and SAHA/CBHA. This classification may prove of value in selecting and planning prospective preclinical and clinical studies toward the treatment of cancer by differentiation therapy.
Richon
V M
VM
Program of Cell Biology and Genetics, DeWitt Wallace Research Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Webb
Y
Y
Merger
R
R
Sheppard
T
T
Jursic
B
B
Ngo
L
L
Civoli
F
F
Breslow
R
R
Rifkind
R A
RA
Marks
P A
PA
D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle; D002454:Cell Differentiation / Q000187:drug effects*; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology; D051379:Mice; D014407:Tumor Cells, Cultured
D000081:Acetamides; D000970:Antineoplastic Agents; C014026:hexamethylene bisacetamide